Regeneron: FDA Accepts Odronextamab Lymphoma Drug Resubmission
Regeneron last year won European Commission approval of odronextamab as Ordspono for relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma after two or more lines of systemic ...
Hosted on MSN26d
Regeneron beats quarterly estimates on eczema drug demand; launches dividend program
(Reuters) - Regeneron Pharmaceuticals beat fourth-quarter sales ... by lower inventory levels and a lower net selling price compared to a year ago. The Tarrytown, New York-based drugmaker's board also ...
yonkerstimes6d
Applications open for Regeneron STEM Teaching Fellowship – now through April 1
The STEM Leadership Center, a Westchester County based nonprofit, in partnership with Regeneron Pharmaceuticals, Inc. and ...
SFGate26d
Regeneron: Q4 Earnings Snapshot
Regeneron Pharmaceuticals Inc. (REGN) on Tuesday reported fourth-quarter earnings of $917.7 million. On a per-share basis, the Tarrytown, New York-based company said it had profit of $8.06.